Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record.

Titration to Target Dose of Bisoprolol vs. Carvedilol in Elderly Patients with Heart Failure: The CIBIS-ELD Trial

Open access
Düngen, Hans-Dirk, Apostolović, Svetlana, Inkrot, Simone, Tahirović, Elvis, Töpper, Agnieszka, Mehrhof, Felix, Prettin, Christiane, Putniković, Biljana, Nešković, Aleksandar N., Krotin, Mirjana, Sakač, Dejan, Lainščak, Mitja, Edelmann, Frank, Wachter, Rolf, Rau, Thomas, Eschenhagen, Thomas, Doehner, Wolfram, Anker, Stefan D., Waagstein, Finn, Herrmann-Lingen, Christoph, Gelbrich, Goetz, Dietz, Rainer · 2011 · European Journal of Heart Failure

Abstract

Aims: Various beta-blockers with distinct pharmacological profiles are approved in heart failure, yet they remain underused and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the tolerability and clinical effects of two proven beta-blockers in elderly patients with heart failure. Methods and results: We performed a double-blind superiority trial of bisoprolol vs. carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres. The primary endpoint was tolerability, defined as reaching and maintaining guideline-recommended target doses after 12 weeks treatment. Adverse events and clinical parameters of patient status were secondary endpoints. None of the beta-blockers was superior with regards to tolerability: 24% [95% confidence interval (CI) 20–28] of patients in the bisoprolol arm and 25% (95% CI 21–29) of patients in the carvedilol arm achieved the primary endpoint (P= 0.64). The use of bisoprolol resulted in greater reduction of heart rate (adjusted mean difference 2.1 b.p.m., 95% CI 0.5–3.6, P= 0.008) and more, dose-limiting, bradycardic adverse events (16 vs. 11%; P= 0.02). The use of carvedilol led to a reduction of forced expiratory volume (adjusted mean difference 50 mL, 95% CI 4–95, P= 0.03) and more, non-dose-limiting, pulmonary adverse events (10 vs. 4%; P < 0.001). Conclusion: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfr020

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 181

Metadata

Authors
Düngen, H.-D., Apostolović, S., Inkrot, S., Tahirović, E., Töpper, A., Mehrhof, F., Prettin, C., Putniković, B., Nešković, A. N., Krotin, M., Sakač, D., Lainščak, M., Edelmann, F., Wachter, R., Rau, T., Eschenhagen, T., Doehner, W., Anker, S. D., Waagstein, F., Herrmann-Lingen, C., Gelbrich, G., & Dietz, R.
Venue
European Journal of Heart Failure
Published
2011-06-01
Volume
13
Issue
6
Pages
670-680
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2088759164
Cited by
181
References
0
FWCI
10.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Titration to Target Dose of Bisoprolol vs. Carvedilol in Elderly Patients with Heart Failure: The CIBIS-ELD Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hfr020
The paper
Düngen, H.-D., Apostolović, S., Inkrot, S., Tahirović, E., Töpper, A., Mehrhof, F., Prettin, C., Putniković, B., Nešković, A. N., Krotin, M., Sakač, D., Lainščak, M., Edelmann, F., Wachter, R., Rau, T., Eschenhagen, T., Doehner, W., Anker, S. D., Waagstein, F., . . . Dietz, R. (2011). Titration to Target Dose of Bisoprolol vs. Carvedilol in Elderly Patients with Heart Failure: The CIBIS-ELD Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfr020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.